Showing 14,701 - 14,720 results of 19,121 for search 'Libu~', query time: 1.21s Refine Results
  1. 14701
  2. 14702
  3. 14703
  4. 14704
  5. 14705
  6. 14706
  7. 14707
  8. 14708
  9. 14709

    T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint pr... by Stephanie Schlichtner, Inna M Yasinska, Gurprit S Lall, Steffen M Berger, Sabrina Ruggiero, Dietmar Cholewa, Nijas Aliu, Bernhard F Gibbs, Elizaveta Fasler-Kan, Vadim V Sumbayev

    Published 2023-01-01
    “…Our aims were to elucidate whether T cells can induce galectin-9 secretion in human cancer cells derived from solid malignant tumors and whether this soluble form displays higher systemic immunosuppressive activity compared with the cell surface-based protein.Methods A wide range of human cancer cell lines derived from solid tumours, keratinocytes and primary embryonic cells were employed, together with helper and cytotoxic T cell lines and human as well as mouse primary T cells. …”
    Get full text
    Article
  10. 14710

    Nonacademic predictors of China medical licensing examination by Jie Sun, Yingying Xie, Ningnannan Zhang, Jingliang Cheng, Meiyun Wang, Bing Zhang, Wenzhen Zhu, Hui Zhang, Shijun Qiu, Xiaojun Xu, Yongqiang Yu, Tong Han, Zuojun Geng, Weihua Liao, Bo Gao, Wen Qin, Feng Liu, Meng Liang, Qiang Xu, Jilian Fu, Jiayuan Xu, Mengge Liu, Peng Zhang, Wei Li, Dapeng Shi, Caihong Wang, Xi-Nian Zuo, Quan Zhang, Feng Chen, Jiance Li, Zhihan Yan, Wen Shen, Yanwei Miao, Junfang Xian, Longjiang Zhang, Kai Xu, Zhaoxiang Ye, Jing Zhang, Guangbin Cui, Chunshui Yu, for the CHIMGEN Consortium

    Published 2025-01-01
    “…Methods In 1202 medical students, we conducted the deletion-substitution-addition (DSA) and structural equation model (SEM) analyses to identify nonacademic predictors of GMKT performance from 98 candidate variables including early life events, physical conditions, psychological and personality assessments, cognitive abilities, and socioeconomic conditions. …”
    Get full text
    Article
  11. 14711

    Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection by Song Dong, PhD, Bingfa Yan, PhD, Si-Yang Liu, PhD, Xuan Gao, PhD, Hui-Zhao Hong, MD, Hong-Ji Li, MD, Wei Gao, PhD, Hong-Hong Yan, PhD, Si-Yang Maggie Liu, PhD, Hai-Yan Tu, PhD, Yi Pan, PhD, Qing Zhou, PhD, Xue-Ning Yang, PhD, Xue-Feng Xia, PhD, Xin Yi, PhD, Wen-Zhao Zhong, PhD, Yi-Long Wu, MD, Jia-Tao Zhang, PhD

    Published 2025-01-01
    “…Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA EGFR-mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease (MRD)-guided de-escalation strategy warrants further investigation. …”
    Get full text
    Article
  12. 14712
  13. 14713
  14. 14714
  15. 14715
  16. 14716
  17. 14717
  18. 14718
  19. 14719
  20. 14720